TSC22D4 (TSC22 domain family member 4) functions as a transcriptional repressor that plays critical roles in metabolic homeostasis and disease progression. The protein acts as a negative regulator of insulin signaling and glucose metabolism, with hepatic TSC22D4 inhibition preventing and reversing hyperglycemia, glucose intolerance, and insulin resistance in diabetic mouse models 1. TSC22D4 exerts these metabolic effects through direct transcriptional regulation of targets including lipocalin 13 (LCN13), and its expression correlates with decreased insulin sensitivity and hyperglycemia in human diabetic patients 1. In liver disease, hepatocyte-specific TSC22D4 activity promotes progressive NAFLD by impairing mitochondrial function, with knockout mice showing reduced liver lipid accumulation and improved steatosis scores 2. TSC22D4 also contributes to liver fibrosis by promoting TGF-β1-induced activation, proliferation, and migration of hepatic stellate cells 3. Beyond metabolic functions, TSC22D4 participates in osmotic stress responses through interaction with the WNK signaling pathway, forming complexes with WNK1, SPAK, and NRBP1 4. The protein shows cell-type-specific expression patterns and has been identified as a co-regulated target with APOE in brain cells 5. These findings establish TSC22D4 as a key therapeutic target for diabetes and liver disease.